What is Dreem?
Founded in 2014, Dreem is dedicated to revolutionizing sleep care by providing effective solutions for individuals, employers, and healthcare providers. The company's core objective is to establish itself as the preeminent global authority in screening, diagnosing, and treating sleep disorders. Dreem has amassed 30 patents and assembled a team of 90 professionals across New York, Paris, and Taipei. Its scientific advisory board comprises four distinguished sleep doctors and neuroscientists, reinforcing the company's commitment to scientific rigor and research. Dreem's proprietary hardware is utilized in academic institutions and hospitals worldwide for sleep studies, including prestigious centers like the Stanford Sleep Center and Harvard Medical School.
How much funding has Dreem raised?
Dreem has raised a total of $61M across 3 funding rounds:
Unspecified
$4M
Private Equity
$22M
Private Equity
$35M
Unspecified (2016): $4M with participation from Laurent Alexandre and Xavier Niel
Private Equity (2017): $22M led by Dr. Laurent Alexandre, Xavier Niel, and MAIF
Private Equity (2018): $35M supported by JJDC and Bpifrance
Key Investors in Dreem
MAIF
MAIF is a French insurance company founded in 1934, offering a range of insurance products including automobile, life, and home coverage. It also provides health and death insurance solutions, demonstrating a broad interest in personal well-being and financial security.
JJDC
JJDC, part of Johnson & Johnson Innovation, focuses on investing in early-stage healthcare companies. Their involvement suggests a strategic interest in Dreem's innovative approach to sleep disorders, aligning with Johnson & Johnson's broader mission in pharmaceuticals and medical technologies.
Bpifrance
Bpifrance is a French public investment bank that supports companies across all stages of development through financing, guarantees, and equity. Their investment in Dreem indicates a commitment to fostering innovation and growth within the French and European technology and healthcare sectors.
What's next for Dreem?
With its substantial enterprise-level backing and a recent strategic investment, Dreem is poised for significant expansion and innovation. The company's focus on scientific validation, evidenced by its patent portfolio and collaborations with leading academic institutions, positions it for continued growth in the digital therapeutics and sleep science markets. Future endeavors will likely involve scaling its diagnostic and treatment platforms, further research into sleep disorder mechanisms, and broadening its global reach to address the widespread impact of sleep health.
See full Dreem company page
